RxDoctor Payments Data

Julia Sass

Psychiatric/Mental Health · Davenport, IANPI 1003539784

Payments from drug & device makers

$2,182in general payments, 2019–2025

Across 103 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$513
  • Otsuka America Pharmaceutical, Inc.$303
  • AbbVie$268
  • Teva Pharmaceuticals USA, Inc.$256
  • Axsome Therapeutics, Inc.$157
  • Alkermes, Inc.$117
  • plus $568 from 12 others

What the payments were for

  • Food & beverage$1,97591%
  • Education$2079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,182 in reported general payments places this provider in the 70th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$10,764
Medicare patients
56
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$104,322
Invega SustennaPaliperidone Palmitate17$58,300
RexultiBrexpiprazole19$30,282
Aripiprazole78$19,279
BelsomraSuvorexant36$15,520
TrintellixVortioxetine Hydrobromide18$11,661
Clozapine21$1,924
Bupropion XlBupropion Hcl83$1,732
Paliperidone ErPaliperidone11$1,648
Quetiapine Fumarate74$1,451
Vilazodone Hcl14$1,281
Divalproex Sodium ErDivalproex Sodium29$1,208
Oxcarbazepine18$1,130
Trazodone Hcl101$942
Valproic AcidValproic Acid (As Sodium Salt)16$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$256$104,32217 claims
Johnson & JohnsonInvega Sustenna$77$58,30017 claims
Otsuka America Pharmaceutical, Inc.Rexulti$303$30,28219 claims
MerckBelsomra$31$15,52036 claims
Almatica Pharma LLCSertraline Hcl$20$60677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →